retatrutide ada 2025 results Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Lilly's triple agonist achieves 16.8%

Retatrutide is a new weight-loss injection made by Eli Lilly

See who qualifies

A shortage of Adderall, which is used to treat attention deficit hyperactivity disorder, shows little sign of easing as manufacturers struggle to get enough active ingredient to make the drug and demand climbs

These trends suggest that GLP-1s are reshaping treatment patterns most significantly in markets where few alternatives exist and where their effectiveness is increasingly valued

Results will be submitted for publication in an international peer-reviewed scientific journal

Ozempic will be a 'big disruptor for the food industry,' says Mattson, which is expanding to Chicago with the acquisition of Hyde Park Group.